Investor Information Archives - Page 4 of 8

Psyence BioMed Webinar For Investors And Shareholders, Featuring Members Of Its Scientific Advisory Board.

Psyence Group2025-09-03T16:01:58+02:00September 3, 2025|Investor Information, Press, Psychedelic News|

Psyence BioMed will host an exclusive investor and shareholder webinar on September 16, 2025, at 12:00 PM EST, featuring members of its Scientific Advisory Board. The session will highlight the Company’s ongoing clinical development programs and share insights into future strategic initiatives, with expert contributions from Dan Stein, Seth Feuerstein, Albert Garcia-Romeu, and Clive Ward-Able.

Corporate Update – August 2025

Psyence Group2025-08-04T14:34:42+02:00August 4, 2025|Investor Information, Press Releases, Psychedelic News|

Over the past few months, Psyence BioMed (PBM) has made meaningful progress across several fronts: clinical development, strategic positioning, regulatory compliance, and manufacturing stability. These developments reflect not only a shift in our momentum but also a broader evolution of the company.

Psyence BioMed’s Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production

Psyence Group2025-07-31T14:51:56+02:00July 31, 2025|Investor Information, Press, Press Releases|

Psyence Biomed is pleased to announce that its strategic partner, PsyLabs – a leader in the production of purified psychedelic compounds – has successfully produced a GMP-aligned Ibogaine Total Alkaloid extract.

Psyence BioMed Regains Full Compliance with Nasdaq Continued Listing Requirements

Psyence Group2025-06-17T09:38:38+02:00June 17, 2025|Investor Information, Press Releases, Psychedelic News|

Psyence Biomedical Ltd. announced that it has received formal notification from the Nasdaq Hearings Panel confirming that the Company has regained compliance with all applicable Nasdaq continued listing requirements. This confirmation follows a successful compliance hearing held on May 29, 2025.

Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial

Psyence Group2025-05-27T14:44:03+02:00May 27, 2025|Investor Information, Press Releases, Psychedelic News|

Psyence Biomed announced the finalization of its service agreement with Southern Star Research Pty Ltd (“Southern Star Research”), an award-winning, full-service Australian Contract Research Organization (CRO).

Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Psyence Group2025-04-21T08:16:12+02:00April 21, 2025|Investor Information, Press Releases, Psychedelic News|

Psyence BioMed announced today that it received a notification letter dated April 16, 2025, from the Listings Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Rule”). The Staff's determination is based on the closing bid price of the Company’s common shares being below $1.00 for 30 consecutive business days from March 5, 2025 through April 15, 2025.

Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement

Psyence Group2025-04-15T14:50:08+02:00April 15, 2025|Investor Information, Press Releases, Psychedelic News|

Psyence BioMed today announced a strategic follow-on investment of USD $500,000 into PsyLabs, a privately-held company specializing in the production of psychedelic active pharmaceutical ingredients (APIs) and extracts for research, clinical trials, and drug development.

Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia

Psyence Group2025-04-09T09:40:45+02:00April 9, 2025|Investor Information, Press Releases, Psychedelic News|

New partnership strengthens Psyence BioMed’s global clinical trial capabilities, accelerating the development of psilocybin-assisted therapy for adjustment disorder

Psyence Biomedical LTD Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing

Psyence Group2025-03-31T14:48:31+02:00March 31, 2025|Investor Information, Press Releases, Psychedelic News|

Appointment adds significant clinical and scientific expertise in the field of psychedelic-based therapies

Corporate Webinar – April 10, 2025

Psyence Group2025-03-19T14:38:41+02:00March 19, 2025|Investor Information, Press Releases, Psychedelic News|

Appointment adds significant clinical and scientific expertise in the field of psychedelic-based therapies

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.